PSMA PET for the Staging and Management of Hepatocellular Carcinoma
ConditionHepatocellular Carcinoma (HCC)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVA Office of Research and Development
About this trial
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Eligibility criteria
Qualifiers
Adult patients age >18 years from the VA medical system
Treatment-naïve patients with HCC with BCLC B or C disease
Disqualifiers
Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging
Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years
Trial design
Treatments tested in this trial
- Not listed
Trial groups
90 Participants
are grouped into 3 trial groupsSponsors and collaborators
VA Office of Research and Development
Lead sponsor
Miami VA Healthcare System
Collaborator
VA Medical Center-West Los Angeles
Collaborator
Source ClinicalTrials.gov